Intervention

Pembrolizumab injection

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting4

Common conditions10

Lead sponsors shown6

Clinical trials

6 shown

A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast CancerNCT07679360 · 2026-09-02

Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and SurgeryNCT05973864 · 2025-03-11

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALKNCT05266846 · 2024-05-29

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid TumorsNCT05746897 · 2023-04-13

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With PembrolizumabNCT06371807 · 2024-07-01

NOT_YET_RECRUITING

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)NCT04964479 · 2021-08-06

Common conditions

Triple Negative Breast Cancer3 ALK Gene Mutation1 Colorectal Cancer1 Early Breast Cancer1 Immunotherapy1 Lung Adenocarcinoma1 Melanoma1 Non Small Cell Lung Cancer1 Ovarian Cancer1 Triple Negative Breast Neoplasms1

Leading sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1 Fundacao Champalimaud1 Hefei TG ImmunoPharma Co., Ltd.1 Hunan Province Tumor Hospital1 Suzhou Suncadia Biopharmaceuticals Co., Ltd.1 UNICANCER1

Trial status mix

RECRUITING4

NOT_YET_RECRUITING1

UNKNOWN1

Phase mix

PHASE23

PHASE32

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.